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Abstract
Background: Frailty increases the risk of adverse health outcomes and/or dying when exposed to a stressor, and routine frailty assessment is 
recommended to guide treatment decision. The Balducci frailty criteria (BFC) and Fried frailty criteria (FFC) are commonly used, but these are 
time consuming. Vulnerable Elders Survey-13 (VES-13) score of ≥7, a simple and resource conserving function-based scoring system, may be 
used instead. This prospective study evaluates the performance of VES-13 in parallel with BFC and FFC, to identify frailty in elderly patients 
with early-stage cancer.
Methods: Patients aged ≥70 years with early-stage solid tumors were classified as frail/nonfrail based on BFC (≥1 criteria), FFC (≥3 criteria), 
and VES-13 (score ≥ 7). All patients were assessed for functional decline and death.
Results: We evaluated 185 patients. FFC had a 17% frailty rate, whereas BFC and VES-13 both had 25%, with poor concordance seen 
between the three geriatric tools. FFC (hazard ratio = 1.99, p = .003) and VES-13 (hazard ratio = 2.81, p < .001) strongly discriminated for 
functional decline, whereas BFC (hazard ratio = 3.29, p < .001) had the highest discriminatory rate for deaths. BFC and VES-13 remained 
prognostic for overall survival in multivariate analysis correcting for age, tumor type, stage, and systemic treatment.
Conclusions: A VES-13 score of ≥7 is a valuable discriminating tool for predicting functional decline or death and can be used as a frailty-
screening tool among older cancer patients in centers with limited resources to conduct a comprehensive geriatric assessment.
Keywords: Frailty—Vulnerable Elders Survey-13—Balducci frailty criteria—Fried frailty criteria—Cancers
Aging is associated with a progressive decline in functional reserve 
of multiple organs and systems. This physiological event occurs at 
varying degrees in the older population implying different levels of 
susceptibility. Susceptible patients are at higher risk of a number of 
negative health outcomes and are more likely to develop treatment 
complications (1). This is concerning in older cancer patients where 
age-related changes can affect tolerance to anticancer therapy and 
can shift the overall risk–benefit ratio of treatment. Early recog-
nition of patients at risk may allow for “risk-adapted” therapy 
approaches.
Frailty is a clinical state in which there is an increased vulner-
ability to develop dependency and/or mortality when exposed to a 
stressor (2). Both cancer and its treatment are significant stressors, 
making the concept of frailty a relevant issue (3), as frail older cancer 
patients are at risk of overtreatment. In the geriatric medicine set-
ting, frailty is not considered to be the end point of the continuum 
of “fit to completely dependent.” Rather, it represents a state where 
an individual may be independent but at high risk of developing 
disability (4). Frailty is often subtle or asymptomatic (5), is either 
physical, psychological, or both, and is a dynamic condition that can 
improve or worsen over time (6). A consensus group consisting of 
delegates from six major international, European, and U.S. societies 
has agreed that all persons aged ≥70 years should be screened for 
frailty for the purpose of optimally managing individuals with physi-
cal frailty (6), and a systematic review of observational studies that 
reported data on the prevalence and/or outcomes of frailty in older 
cancer patients support routine frailty assessment in older cancer 
patients to guide treatment decision (7), yet there remains an incon-
sistent use of this concept in oncology and geriatric medicine (4).
There is still no consensus on the measurement of frailty in older 
adults with cancer (3). The Balducci frailty criteria (BFC) and Fried 
frailty criteria (FFC) are two common measures used to identify frail 
patients (8–10). BFC define frailty based on fulfilling any of the follow-
ing criteria from the components of comprehensive geriatric assessment 
(CGA): dependence in one or more activities of daily living (ADL), 
three or more comorbidities, and/or one or more geriatric syndromes 
(8,11). FFC are based on the cardiovascular health study (CHS) tool, 
an instrument developed to identify frailty based on the presence of 
three or more of the following: unintentional weight loss (≥10 lbs 
in the past year), self-reported exhaustion, weakness (grip strength), 
slow observed walking speed, and/or low physical activity based on 
an algorithm that translates patient-reported activities into kilocalories 
expended (10). A prospective observational study on frailty status has 
reported these criteria to be predictive of incidental falls, worsening 
mobilization or ADL function, incidence of hospitalization, and death 
(10). The Vulnerable Elders Survey-13 (VES-13) is a self-reported func-
tion-based scoring system that considers age, self-rated health, physical 
performance, and functional status (12). It defines a group of patients 
with a score of ≥3 as vulnerable, which has 4.2 times the risk of death 
or functional decline over a 2-year period compared with patients with 
scores <3 (12). Min and colleagues have shown in prospective stud-
ies that higher VES-13 scores are associated with a greater predicted 
probability of death and decline among older patients, both at short- 
and long-term follow-ups (13,14). This has been proven as a useful 
screening tool for detecting risk of health deterioration in already vul-
nerable older patients, with higher VES-13 scores (7–10) reflecting an 
even much greater risk than those with lower VES-13 scores (3–6) (13). 
Rodin and Mohile have suggested that VES-13 score of ≥7 could be 
used to identify frail cancer patients (15).
Our group previously published the results of a prospective 
observational study that evaluated the role of CHS and VES-13 in 
predicting CGA abnormalities in a mixed population of older cancer 
patients with early or advanced disease (16). Because frail patients 
are more susceptible to functional decline and death (2,8,17,18), 
we then prospectively evaluated the performance of three geriatric 
assessment tools in defining frailty by observing the incidence of 
these two events over time. We were particularly interested in evalu-
ating the performance of VES-13, a simple and resource conserving 
test, in parallel with two well-established assessment tools for frailty, 
such as CGA-based BFC and CHS-based FFC. We present the results 
of these analyses in this article.
Materials and Methods
Patients
Eligible patients aged ≥70  years with early-stage solid tumors 
referred to Medical Oncology Clinic for systemic adjuvant therapy 
and/or surveillance/follow-up after surgical resection of the primary 
tumor were recruited consecutively and classified as frail/nonfrail 
based on BFC (domains investigated in CGA, tests, and scores 
used have been described elsewhere) (16), FFC, and VES-13 scores. 
Patients were classified as frail if they had ≥1 disability in ADL, and/
or ≥3 Grade 3 or ≥1 Grade 4 comorbidities at cumulative illness rat-
ing scale modified for geriatric patients (CIRS-G), and/or ≥1 geriatric 
syndrome at CGA; ≥3 abnormalities at CHS; or a score of ≥7 at VES-
13. CIRS-G was used to evaluate comorbidities as it provides a more 
comprehensive assessment, allows severity rating for all the diseases 
identified, and is more sensitive to individual variation (19). Patients 
had a follow-up, planned visit or phone interview at a 6-monthly 
interval. All patients were assessed for functional decline and death.
The protocol was approved by the institutional review board and 
ethics committee. All patients provided written informed consent 
before study entry.
Statistical Analysis
The distributions of demographic, clinical, and biologic characteris-
tics of all studied patients were summarized as frequencies and per-
centage. Continuous variable was reported as median and range of 
variation. The concordance between the results of the three geriatric 
tests was evaluated by kappa concordance (k > 0.7 was considered 
concordant).
The outcomes of interest were time to functional event (TFE), 
overall survival (OS), and event-free survival (EFS). Functional 
decline or functional event (FE) was defined as either occurrence of 
dependence—a change from no ADL or instrumental ADL impair-
ment to any ADL or instrumental ADL impairment—or worsening 
of previous dependence—a loss of ≥2 in instrumental ADL or ≥1 in 
ADL score. Date and cause of death (tumor related or tumor inde-
pendent, the latter defined as an event occurring in patients free from 
cancer recurrence) were documented. Global event (GE) was defined 
as the occurrence of a FE or death without previous functional 
loss, whichever occurred first. TFE was defined as the time interval 
between the date of informed consent and FE. OS was computed 
as the interval between the date of informed consent and death. 
EFS was defined as the time interval between the date of informed 
consent and GE. Observation time of patients alive and/or without 
functional decline at the last follow-up was censored. Inability to 
ascertain outcomes 18 months after last contact was defined as loss 
to follow-up.
The distributions of TFE, EFS, and OS were estimated using 
the Kaplan–Meier method and compared with the log-rank test. 
BFC, FFC, and VES-13 (nonfrail vs frail) were investigated for their 
impact on TFE, EFS, and OS. Hazard ratios (HR) with 95% con-
fidence intervals (CI) were calculated using the Cox proportional 
hazards model. Likelihood ratio test was used to determine the sta-
tistical significance of all coefficients.
Demographic and clinical variables were dichotomized and 
investigated for their impact on OS: age at study entry (<80 vs 
≥80 years), site of tumor (breast vs nonbreast), stage of tumor (I–II 
vs III), and systemic adjuvant therapy (yes vs no). A multivariate Cox 
regression model evaluated the independent effect of each covariate 
on OS. Using stepwise selection, we created a model that includes all 
significant covariates, a probability of .05 was used for both entry 
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and stay criteria. Median follow-up time was estimated according 
to the Kaplan–Meier inverse method. Data were analyzed using the 
statistical software SAS 9.3 (SAS Corporation, Cary, NC).
Results
We identified 192 patients with early-stage cancers from Sandro 
Pitigliani Medical Oncology Department, between November 2008 and 
June 2011; 7 (3.6%) patients refused geriatric assessments and were 
excluded from the study. The remaining 185 patients had frailty assess-
ments and were evaluable for analyses; 2 patients were loss to follow-up 
after 30 and 49 months, respectively. Major patient and disease charac-
teristics are reported in Table 1. The median age was 77 years, median 
Eastern Cooperative Oncology Group (ECOG) performance status 
was 0 (range 0–3), majority were women (80%) and had breast cancer 
(65%); 81% received adjuvant systemic therapy. The frailty rate was 
17% in FFC and 25% for both BFC and VES-13. The three geriatric 
tools had poor concordance in classifying frailty, with only 9% catego-
rized as frail in all three evaluations (Supplementary Table).
There were 162 events (functional and death) reported at a 
median follow-up of 55.2  months (interquartile range  =  47.3–
65.5 months). Details are reported in Table 2.
Functional Events
FE were reported in 114 patients. In 55% of the cases, the FE 
was related to ADL impairment. Table 3 summarized the distribu-
tion of FE at different time points based on baseline frailty status 
according to BFC, FFC, and VES-13. Based on FFC, median TFE 
in nonfrail and frail patients was 26.4 and 14.4  months, respec-
tively, HR = 1.99 (95% CI = 1.24–3.19), p =  .003. From VES-13, 
TFE was 36.5 months in nonfrail and 12.9 months in frail patients, 
HR = 2.81 (95% CI = 1.88–4.21), p < .001. There was no difference 
in FE between nonfrail and frail patients with BFC. Kaplan–Meier 
curves for FE are shown in Figure 1.
Death Events
Overall, 48 patients died during the study period, with date of 
death ranging from 20  days to 64  months after study enrolment. 
All three tools showed significant prognostic value for OS (Figure 2) 
and predicted both early and long-term outcomes (Table 3). Of the 
three tools, BFC had the highest discriminatory power and FFC the 
lowest. Median survival times were 57.2 and 63.8 months for frail 
patients from BFC and VES-13, respectively. Median survival was 
not reached in all three groups of nonfrail patients. HR for survival 
(nonfrail vs frail) were 3.29 (95% CI  =  1.86–5.80), p < .001 for 
BFC, 2.03 (95% CI = 1.07–3.84), p = .026 for FFC, and 2.61 (95% 
CI = 1.48–4.62), p = .001 for VES-13. In multivariate analysis cor-
recting for age, tumor type, stage of disease, and systemic treatment, 
BFC and VES-13 remained prognostic factors for OS (Table 4).
There were 14 deaths classified as tumor independent (Table 2). 
Analysis of tumor-independent deaths showed a strongly signifi-
cant prognostic value for OS for both BFC and VES-13 (p < .001; 
Supplementary Figure).
Global Events
There were 136 GE registered. All three tools predicted both early 
and long-term EFS (Table  3). Median EFS was 24.2, 25.3, and 
26.6 months in nonfrail patients and 18.8, 12.2, and 12.2 months in 
frail patients at BFC, FFC, and VES-13, respectively. Corresponding 
HR were 1.50 (95% CI = 1.04–2.17), p = .029 for BFC, 2.29 (95% 
CI = 1.51–3.48), p < .001 for FFC, and 2.94 (95% CI = 2.04–4.25), 
p < .001 for VES-13.
Discussion
Frailty confers a greater risk for adverse events or negative health 
outcomes, that is, falls, disability, toxicity, hospitalization, and mor-
tality when exposed to stressors. Thus, measuring frailty in older 
adults with cancer may identify those at higher risk for these out-
comes. Because frail patients are more susceptible to functional 
decline and death, we observed the incidence of these events pro-
spectively, comparing the performance of three geriatric assessment 
tools to define frail versus nonfrail in older cancer patients with 
early-stage disease.
A systematic review including 21 studies of frailty in persons 
aged ≥65 years found a 4%–17% prevalence of physical frailty, and 
this increased further when psychosocial frailty was included (20). 
Because cancer is a stressor, it is expected to find an even higher 
frailty rate in older cancer patients. More recently, Handforth and 
colleagues performed a systematic review of 20 observational studies 
in older cancer patients (all stages) and reported a frailty prevalence 
of 6%–86% (7). Our study identified a 17%–25% frailty status. 
These highlight the major role of geriatric assessment in identifying 
Table 1. Baseline Patient and Disease Characteristics 
Baseline Characteristics Number %
Median age, y (range) 77 (70–91)
Gender
 Male 37 20
 Female 148 80
Education, y
 0–4 59 32
 5–7 102 55
 8–12 15 8
 13–18 9 5
ECOG performance status
 0 102 55
 1 61 33
 2 16 9
 3 5 3
 Missing 1 —
Primary disease
 Breast 121 65
 Colorectal 55 30
 Gastric 7 4
 Other 2 1
Prior surgery 185 100
Tumor stage
 I 61 33
 II 70 38
 III 45 24
 Missing 9 5
Frailty status at BFC
 Frail 47 25
 Nonfrail 138 75
Frailty status at FFC
 Frail 31 17
 Nonfrail 154 83
Frailty status at VES-13
 Frail 47 25
 Nonfrail 138 75
Note: BFC = Balducci frailty criteria; ECOG = Eastern Cooperative Oncol-
ogy Group; FFC = Fried frailty criteria; VES-13 = Vulnerable Elders Survey-13.
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frailty even among patients with excellent ECOG performance 
status (88% of patients had ECOG 0–1).
All three geriatric evaluations predicted the probability of GE 
even if BFC had lower discriminatory power than FFC and VES-
13, as suggested by worse HR. This was related to the failure of 
BFC to predict a different incidence of FE between frail and non-
frail patients. Conversely, FFC and VES-13 strongly discriminated 
for functional decline between the two subgroups. This might be 
due to FFC and VES-13 being both mainly focused on detect-
ing functional disabilities, whereas BFC assesses other geriatric 
domains besides function highlighting that different tools might 
predict different outcome measures. Although functional impair-
ments can be effectively identified with CGA and CGA has been 
shown to be predictive of treatment tolerance and mortality (21), 
there have been no clinical studies directly correlating BFC with 
functional decline.
Several studies have evaluated the role of frailty-screening meth-
ods to predict the outcome in elderly patients with cancer. Although 
the outcome was intended to predict CGA impairments rather than 
long-term outcomes in the majority of these studies (3), some studies 
found these screening methods to be predictive of OS (22,23). In our 
study, the three frailty measures significantly predicted OS, with BFC 
having the highest discriminating power, though the CI of the three 
tests overlaps.
To our best knowledge, this study represents the first longitudinal 
evaluation of frailty using VES-13 as a predictive tool for decline or 
death in older cancer patients. The parallel evaluation with BFC and 
FFC, two common measures used to identify frail patients, allows 
calibrating the role of VES-13 in this context. A VES-13 score of ≥7 
was used to define frail patients as this has been previously shown 
to predict a greater risk for death and decline than the ≥3 score in 
vulnerable patients. At a median follow-up of 4.5 years, a VES-13 
score of ≥7 was able to distinguish the frail group of elderly cancer 
patients who nearly had three times the risk of developing functional 
decline and 2.6 times the risk of dying from the nonfrail group. 
These data favorably compare with those obtained with FFC for 
GE, FE, and OS and with BFS for GE and FE. The study also had a 
good participating (96%) and retention rates (99%), making follow-
up bias less likely.
However, the study has limitations that need to be taken into 
account. First, the study was based on a single-center cohort of 
elderly patients with early-stage cancers, limiting generalization. 
Table 2. Distribution of Events Based on Baseline Frailty Status According to BFC, FFC, and VES-13
BFC FFC VES-13
Events
Nonfrail Frail Nonfrail Frail Nonfrail Frail
n = 138 n = 47 n = 154 n = 31 n = 138 n = 47
Global event, n 95 41 107 29 90 46
Functional event, n 85 29 92 22 76 38
Deaths, n 25 23 35 13 27 21
Tumor-independent deaths, n 3 11 9 5 4 10
Note: BFC = Balducci frailty criteria; FFC = Fried frailty criteria; VES-13 = Vulnerable Elders Survey-13.
Table 3. Cumulative Probability of Functional Decline or Death, Probability of Functional Decline, and Probability of Death at Different Time 
Points Based on Baseline Frailty Status According to BFC, FFC, and VES-13
BFC FFC VES-13
Time Points
Nonfrail Frail Nonfrail Frail Nonfrail Frail
n = 138 (%) n = 47 (%) n = 154 (%) n = 31 (%) n = 138 (%) n = 47 (%)
Probability of functional event
 1 y 27 21 24 32 21 41
 2 y 46 38 41 65 37 68
 3 y 56 68 55 82 50 88
 4 y 62 76 61 88 56 96
 5 y 66 76 65 88 60 96
Probability of death
 1 y 2 15 3 16 3 13
 2 y 8 28 11 23 9 23
 3 y 11 40 16 32 13 34
 4 y 13 40 18 32 15 34
 5 y 20 52 26 46 23 48
Probability of global event
 1 y 29 32 27 45 23 49
 2 y 49 51 45 74 41 74
 3 y 59 81 60 90 55 94
 4 y 66 86 67 94 62 98
 5 y 71 89 72 94 68 98
Note: BFC = Balducci frailty criteria; FFC = Fried frailty criteria; VES-13 = Vulnerable Elders Survey-13.
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Second, the treating oncologists were not blinded to frailty out-
come, as they can access the assessment results freely that might lead 
to interventions to minimize death or decline in more vulnerable 
populations or might expose to the possibility of treatment bias. 
Third, the performance of the screening tests might be different in 
various tumor subtypes. However, the study sample size precluded 
Figure 1. (A) Time to functional event (TFE) according to frailty status by Balducci 
frailty criteria (BFC), (B) TFE according to frailty status by Fried frailty criteria (FFC), 
and (C) TFE according to frailty status by Vulnerable Elders Survey-13 (VES-13).
Figure 2. (A) Overall survival (OS) according to frailty status by Balducci frailty 
criteria (BFC), (B) OS according to frailty status by Fried frailty criteria (FFC), 
and (C) OS according to frailty status by Vulnerable Elders Survey-13 (VES-13).
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us from conducting subgroup analysis. At last, the multivariate anal-
ysis for OS included both VES-13 and age. Because VES-13 includes 
age as a rating factor, this could potentially understate the associa-
tion between the outcome and VES-13 score.
Despite these limitations, a VES-13 score of ≥7 is a valuable 
discriminating tool for predicting functional decline. Due to its 
good prognostic value for OS, it can be used as a screening tool for 
frailty among older cancer patients, especially in centers, where 
resources for conducting a comprehensive assessment are limited 
and a two-step screening approach might be considered, that is, 
screening with VES-13 and followed by CGA, if abnormal. In 
centers, where comprehensive evaluation of the health status of 
cancer patients is routinely done, BFC should be used to detect 
frailty instead. More importantly, a positive screening test for 
frailty must not be used to exclude frail patients from a potentially 
curative treatment. Even with the limitation of the small number 
of events reported, survival analysis for tumor-independent events 
(an analysis that is free from the impact of tumor on the risk of 
dying) showed that 70% of frail patients were alive at 5  years 
from study entry.
In this study, we did not investigate whether a VES-13 score of 
≥7 predicts for higher treatment-related toxicity. However, Luciani 
and colleagues have previously shown that a standard VES-13 score 
of ≥3 can identify vulnerable patients at risk for Grades 3–4 hemato-
logical and nonhematological toxicities (24).
Frailty exposes older patients to adverse outcomes. Identifying 
frailty in elderly cancer patients may allow for a risk-adapted 
approach that includes personalized treatments, close monitoring, 
and proactive management of toxicities. VES-13 might be consid-
ered a valuable instrument for this purpose.
Supplementary Material
Supplementary data are available at The Journals of Gerontology: 
Series A online.
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